SENDERO HEALTH PLANS

Prior Authorization Request Form	**Orencia**
Sendero Fax: 512-901-9724	**Phone:** 855-297-9191
URGENCY: ☐ **STANDARD**	☐ **URGENT (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health or ability to regain maximum function)**

Provider Information	**Patient Information**
Referring/Prescribing Physician: ☐ **PCP** ☐ **Specialist** **Name:** **Please identify SPECIALTY:** **DEA, NPI or TIN:** **Contact:** **Phone: ( ) Fax: ( )**	**Patient's Name:** **Birth Date:** **ID Number:** **Phone Number:** **Patient Height:** **Patient Weight:**
Indicate where the drug is being DISPENSED	**Indicate where the drug is being ADMINISTERED**
☐ **Ambulatory Surgery Center** ☐ **Home Care Agency** ☐ **Inpatient Hospital** ☐ **Long Term Care** ☐ **Outpatient Hospital** ☐ **Patient's Home** ☐ **Pharmacy** ☐ **Physician's Office** ☐ **Other (explain):**	☐ **Ambulatory Surgery Center** ☐ **Inpatient Hospital** ☐ **Long Term Care** ☐ **Outpatient Hospital** ☐ **Patient's Home** ☐ **Pharmacy** ☐ **Physician's Office** ☐ **Other (explain):** **Anticipated Date of Service:**

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

PATIENT CLINICAL INFORMATION

CRITERIA QUESTIONS:

1. Is the product being requested for the treatment of an ADULT patient (18 years of age or older)* with one of the following indications?
   - ☐ Psoriatic arthritis
   - ☐ Rheumatoid arthritis (RA)
   - ☐ Juvenile Idiopathic Arthritis (polyarticular) – *exception – includes pediatric patients
   - ☐ Other: _____
2. What is the requested drug? ☐ Orencia SQ ☐ Orencia IV
3. What is the HCPCS code? _____ What is the ICD-10 code? _____
   What is the NDC#: _____
4. Will the requested drug be used in combination with any other biologic or targeted synthetic DMARD (e.g., Olumiant, Xeljanz)? ☐ Yes ☐ No
5. Has the patient had a TB screening test (e.g., a tuberculosis skin test [PPD] or an interferon-release assay [IGRA]) within 6 months of initiating therapy? ☐ Yes ☐ No
6. What were the results of the TB screening test? ☐ Positive ☐ Negative
7. Does the patient have latent or active tuberculosis (TB)? ☐ Latent ☐ Active ☐ No/Neither
8. If the patient has latent or active tuberculosis, has treatment been initiated or completed?
   ☐ Yes - treatment initiated ☐ Yes - treatment completed ☐ No
9. Is this request for continuation of therapy? ☐ Yes ☐ No

10. For continuation of therapy requests, has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms since starting treatment with the requested drug? ☐ Yes ☐ No

11. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? ☐ Yes ☐ No

DIAGNOSIS QUESTIONS: ***Please only complete sections below that are relevant to the patient's diagnosis.***

Section A. RHEUMATOID ARTHRITIS

12. The patient has diagnosis of rheumatoid arthritis and the treatment is prescribed by or in consultation with a rheumatologist. ☐ Yes ☐ No

13. Has the patient previously received a biologic or targeted synthetic DMARD (e.g., Rinvoq, Xeljanz) that is indicated for moderately to severely active rheumatoid arthritis? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:_____

14. Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate 25mg PO weekly? ☐ Yes ☐ No If the methotrexate dose is unable to be increased to 25mg PO weekly, please indicate reason: _____

15. Has the patient experienced intolerance to methotrexate? ☐ Yes ☐ No If Yes, indicate intolerance: _____

16. Does the patient have a contraindication to methotrexate? ☐ Yes ☐ No If Yes, indicate contraindication: _____

* Please note, the preferred class of biologic is a TNF inhibitor (specifically Cimzia), followed by anti-IL-6 therapy (specifically Kevzara), and followed by rituximab. Please consider prescribing 1 of these drugs before Orencia if clinically appropriately. If Orencia is preferred over these agents, please provide additional clinical reasoning documentation here:
_____

Section B: Juvenile Idiopathic Arthritis (polyarticular)

17. Has the patient previously received a biologic indicated for moderately to severely active articular juvenile idiopathic arthritis? ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:
_____

18. Has the patient had an inadequate response to methotrexate or another non-biologic DMARD administered at an adequate dose and duration? ☐ Yes ☐ No

19. Does the patient have any of the following risk factors: a) positive rheumatoid factor or anti-CCP, b) pre-existing joint damage, c) high disease activity or high risk for disabling joint disease? ☐ Yes ☐ No

* Please note, the preferred class of biologic is a TNF inhibitor (specifically Humira), followed by anti-IL-6 therapy (specifically Actemra). Please consider prescribing 1 of these drugs before Orencia if clinically appropriately. If Orencia is preferred over these agents, please provide additional clinical reasoning documentation here:
_____

Section C: Psoriatic Arthritis

20. The patient is diagnosed with psoriatic arthritis and treatment is prescribed by or in consultation with a rheumatologist ☐ Yes ☐ No

21. Has the patient previously received a biologic medication, apremilast (Otezla), or targeted synthetic DMARD (e.g., Xeljanz) indicated for the treatment of psoriatic arthritis? ☐ Yes ☐ No ☐ Yes ☐ No If Yes, please indicate the drug, duration, response, and intolerance/contraindication if applicable:

22. Has the patient experienced an inadequate response after at least 3 months of treatment with 1 or more of the following medications at the maximally tolerated dose?
    - ☐ Methotrexate – minimum dose 15mg po weekly
    - ☐ Sulfasalazine – minimum dose 2g po weekly
    - ☐ Cyclosporine
    - ☐ Leflunomide
    - ☐ Apremilast (Otezla)

23. Does the patient have a contraindication or intolerance to at least 2 options listed above? ☐ Yes ☐ No
    If yes, please document medications and respective contraindications/intolerances:
    _____

* Please note, the preferred class of biologics are TNF inhibitors (specifically Cimzia). If Orencia is preferred, please provide additional clinical reasoning documentation here:
_____

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Sendero Health Plans.	
Prescriber or Authorized Signature	DATE